The Current Status of Orphan Drug Development in Europe and the US

Intractable and Rare Diseases Research - Japan
doi 10.5582/irdr.3.1
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Related search

Orphan Drug Approvals in Europe: Historical Review and Trends

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act

Milbank Quarterly
Health PolicyPublic HealthOccupational HealthEnvironmental
1995English

The Effect of the Orphan Drug Development Support Program.

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
1999English

Patient-Reported Outcomes in Orphan Drug Labels Approved by the US FDA

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Pmu32 - Orphan Drug Prices in Europe: Impact of External Reference Pricing

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Current Status of Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Studies in Drug Development

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
2003English

Current Challenges in Economic and Financial Criminal Law in Europe and the US

English

Psy163 - Identification of Key Orphan Drug Attributes in Predicting the Expected Level of Payer Management in the Us and Eu3

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Current Status of Faculty Development Internationally

International Journal for the Scholarship of Teaching and Learning
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy